Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending

Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc.

ADIL

0.00


Overview

  • U.S. addiction therapies developer's Q1 net loss narrowed from prior year on lower R&D spending

  • Company highlighted regulatory changes that may speed AD04 approval and reduce development costs

  • Adial set collaboration framework with Molteni for potential AD04 commercialization in Europe


Outlook

  • Company expects existing cash to fund operations into the second half of 2026


Result Drivers

  • LOWER R&D SPENDING - Co said Q1 research and development expenses fell due to decreased CMC activity and no new data analytics projects

  • HIGHER BUSINESS DEVELOPMENT COSTS - Co said Q1 general and administrative expenses rose due to increased business development costs


Company press release: ID:nGNX9d27W1


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$2 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $25.00, about 1,648.3% above its May 8 closing price of $1.43


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.